Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
94 hedge funds and large institutions have $85.1M invested in Bellicum Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 11 closing their positions.
24% more capital invested
Capital invested by funds: $68.7M → $85.1M (+$16.4M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
2% more funds holding
Funds holding: 92 → 94 (+2)
11% less call options, than puts
Call options by funds: $85K | Put options by funds: $95K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$3.55M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$3.55M |
| 3 |
Renaissance Technologies
New York
|
+$1.78M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.16M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$919K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.92M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.81M |
| 3 |
Millennium Management
New York
|
-$934K |
| 4 |
SIM
Spark Investment Management
New York
|
-$227K |
| 5 |
BlackRock
New York
|
-$205K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
101
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$4K | -150 | Closed |
|
102
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1.87K | -56 | -98% |
|
|
AIC
103
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$1K | -44 | Closed |
|
|
RIA
104
Realta Investment Advisors
Wilmington,
Delaware
| – | +$33 | +1 | New |
|
105
Marshall Wace
London,
United Kingdom
| – | +$167 | +5 | New |
|
BLCM Hedge Fund Activity: Q1 2019 in Review
94 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2019, worth a combined $85.1M — up 24% from $68.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BLCM positions and 11 closed out — a net gain of 2 holders — while 29 added to existing stakes and 25 trimmed.
The largest buyer was Nikko Asset Management Americas, opening a new position worth an estimated $3.55M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $2.92M sold.
- 94 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2019, up from 92 in Q4 2018.
- Funds reported $85.1M of Bellicum Pharmaceuticals, Inc. stock for Q1 2019, up 24% quarter-over-quarter.
- 13 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2019 and 11 closed out, a net change of +2 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2019 was Nikko Asset Management Americas, an estimated $3.55M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2019 was Farallon Capital Management, an estimated $2.92M sold.
Based on aggregated 13F filings for Q1 2019.